Colonoscopy Bowel Preparation Drugs Market Size to Exceed USD 3,228.5 Mn by 2032

The Colonoscopy Bowel Preparation Drugs Market, estimated at USD 2,309.8 Mn in 2025, is expected to exhibit a CAGR of 4.9% and reach USD 3,228.5 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Increasing incidence of colorectal cancer is driving the market. Modern lifestyles characterized by sedentary habits, unhealthy diets, and obesity have been linked to an increased risk of colorectal cancer. For example, according to WHO statistics in March 2022, more than 1 billion people worldwide are obese – 650 million adults, 340 million adolescents and 39 million children. This number is still increasing. WHO estimates that by 2025, approximately 167 million people – adults and children – will become less healthy because they are overweight or obese. As these lifestyle factors become more prevalent globally, the incidence of colorectal cancer rises, driving the demand for colonoscopy screenings and bowel preparation drugs.

Moreover, gastrointestinal disorders such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis often require regular colonoscopies for monitoring and surveillance. The rising prevalence of these conditions contributes to the demand for colonoscopy bowel preparation drugs. For instance, according to Centers for Disease Control and Prevention data in September 2022, number of adults with diagnosed ulcers were 14.8 million, number of visits to physician offices with diseases of the digestive system as the primary diagnosis were 35.4 million in U.S.

Global Colonoscopy Bowel Preparation Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic led to disruptions in healthcare systems worldwide, including the postponement of elective procedures, including colonoscopies, in many regions. For instance, new estimates from the World Health Organization (WHO) in May 2022 show that the total death toll associated directly or indirectly with the COVID-19 pandemic was approximately 14.9 million (range 13.3 million to 16.6 million).

This temporary disruption had an impact on the demand for colonoscopy bowel preparation drugs, as the number of procedures performed decreased significantly during the height of the pandemic.

Telemedicine and virtual consultations have gained prominence during the COVID-19 pandemic. While colonoscopies require an in-person procedure, telemedicine has been utilized for pre- and post-procedure consultations, as well as for providing instructions for bowel preparation. This shift towards telemedicine has facilitated continued patient engagement and support, helping to maintain the demand for colonoscopy bowel preparation drugs.

Due to the temporary postponement of elective procedures during the pandemic, there may be a backlog of colonoscopy procedures that need to be performed. As healthcare systems catch up on this backlog, there could be a surge in the demand for colonoscopy bowel preparation drugs to ensure effective and efficient procedures.

Global Colonoscopy Bowel Preparation Drugs Market: Key Developments

In September 2022, Lupin Limited, an Indian multinational pharmaceutical company launched the generic Suprep Bowel Prep Kit Oral Solution, used for cleansing the colon as a preparation for colonoscopy, after getting approval from the U.S. Food and Drug Administration.

Browse 28 market data tables and 22 figures spread through 175 Pages and in-depth TOC on “Colonoscopy Bowel Preparation Drugs Market, by Drug Type (Isosmotic Agents, Hyposmotic Agents, Hyperosmotic Agents, and Combination Agents), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

To know the latest trends and insights prevalent in this market, click the link below:
  https://www.coherentmarketinsights.com/market-insight/colonoscopy-bowel-preparation-drugs-market-3641

Key Takeaways of the Global Colonoscopy Bowel Preparation Drugs Market:

• The combination agents segment in the global colonoscopy bowel preparation drugs market was valued at US$ 5 Mn in 2023 and is expected to reach US$ 2796.1 Mn by 2030 at a CAGR of 4.9% during the forecast period. The growth of the segment is attributed to advancements in bowel preparation drugs during the forecasted period.
• The combination agents segment held a dominant position in the global colonoscopy bowel preparation drugs market in 2022, followed by Isosmotic agents, hyposmotic agents, and hyperosmotic agents. With increasing product launches, these segments are poised for growth in the coming years.
• The retail pharmacies segment held a dominant position in the global colonoscopy bowel preparation drugs market in 2022, followed by hospital pharmacies, and others (wholesale distributors, online pharmacies). Manufacturers are continually investing in research and development to develop improved bowel preparation drugs is expected to propel the growth of the market during the forecast period.
• Major players operating in the global colonoscopy bowel preparation drugs market include Ferring B.V., Bayer AG, Braintree, Bausch Health Companies Inc., and Norgine B.V.